Interim Report – January to June 2017

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the second quarter 2017.

Financial Highlights

• Revenue for the 2nd Quarter 2017 amounted to SEK 26.2 (33.6) m, and for the six month period to 57.4 (54.6) m
• Operating result for the quarter amounted to SEK -19.7 (9.2) m, and for the six month period to -17.4 (-2.3) m
• EBITDA for the quarter amounted to SEK -19.4 (9.3) m, and for the six month period to -16.8 (-2.0) m
• Net result for the quarter amounted to SEK -19.6 (9.4) m, and for the six month period to -17.3 (-2.3) m
• Cash flow for the quarter amounted to SEK -54.2 (105.0) m, and for the six month period to -36.2 (125.2) m
• Cash and cash equivalents at the end of the period amounted to SEK 90.9 (132.3) m.

Significant Events during the Reporting Period

• In May it was announced that we have decided to initiate a Phase II development with ABY-035, our proprietary psoriasis program.
• During the quarter MedImmune terminated the agreement primarily as a result of changing R&D priorities.

Significant Events during the rest of the Year

• During the first quarter, the first patient was dosed and evaluated in the clinical trial with ABY-029, to guide cancer surgery.

Significant Events after the Close of the Reporting Period

• In August we filed the clinical trial application (CTA) to progress our psoriasis compound ABY-035 to Phase II.